Auvinen A, Tammela T, Stenman U H, Uusi-Erkkilä I, Leinonen J, Schröder F H, Hakama M
Finnish Centre for Radiation and Nuclear Safety, Helsinki, Finland.
Br J Cancer. 1996 Aug;74(4):568-72. doi: 10.1038/bjc.1996.402.
The possibility of screening the general population for prostate cancer using serum prostate-specific antigen (PSA) level (alone or in combination with other tests) as screening test has recently been discussed. A number of studies are on the way, but the published reports have almost exclusively been based on men volunteering for screening. We assessed the feasibility of a screening study based on men identified from a central population registry. A random sample of 600 men in the age groups 55, 60 and 65 years was identified from the Finnish Population Registry as the study population. Half of them were randomised to the intervention group and an invitation to participate was sent to them. The participation rate was 77% (230 out of 300). Twenty-five men had a serum PSA concentration of 4.0 micrograms l-1 or above and were invited for further examination including digital rectal examination, transrectal ultrasound and transrectal Tru-cut biopsies (directed and/or random). Six cases of cancer were detected among the 230 participating men, which corresponds to a detection rate of 2.6% and a positive predictive value of 24%. The number of cases detected is equivalent to the expected number of prostate cancer cases during a 10 year follow-up in this population. The ratio of free to total PSA was also measured and a cut-off level of 0.20 was chosen. Its use as an additional criterion of the screening test would have decreased the prevalence of false-positive screening tests from 8% (19 of 230) to 3% (7 of 230) at a cost of missing one of the six cancers compared with serum total PSA concentration alone. Of the six cancers, five were clinically regarded as localised and locally confined disease was confirmed pathologically in four of them. In conclusion, a population-based study in Finland seems feasible and the properties of the PSA test can be regarded as suitable for a randomised screening study. Thus, all prerequisites for a multicentre study, which is planned, seem to exist.
近期已对采用血清前列腺特异性抗原(PSA)水平(单独或与其他检测联合)作为筛查试验对普通人群进行前列腺癌筛查的可能性展开了讨论。多项研究正在进行中,但已发表的报告几乎均基于自愿参与筛查的男性。我们评估了一项基于从中央人口登记处识别出的男性开展筛查研究的可行性。从芬兰人口登记处随机抽取了年龄在55岁、60岁和65岁的600名男性作为研究人群。其中一半被随机分配至干预组,并向他们发出了参与邀请。参与率为77%(300人中230人)。25名男性血清PSA浓度达到或高于4.0微克/升,并被邀请进行进一步检查,包括直肠指检、经直肠超声检查和经直肠Tru-cut活检(定向和/或随机)。在230名参与研究的男性中检测出6例癌症,对应检出率为2.6%,阳性预测值为24%。检测出的病例数与该人群10年随访期间预期的前列腺癌病例数相当。还测量了游离PSA与总PSA的比值,并选择了0.20的临界值。与仅使用血清总PSA浓度相比,将其用作筛查试验的附加标准会使假阳性筛查试验的患病率从8%(230人中19人)降至3%(230人中7人),代价是漏诊6例癌症中的1例。在这6例癌症中,5例临床诊断为局限性疾病,其中4例经病理证实为局部局限疾病。总之,在芬兰开展基于人群的研究似乎可行,PSA检测的特性可被视为适用于随机筛查研究。因此,计划中的多中心研究的所有前提条件似乎均已具备。